Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors

International Immunopharmacology

Volumn 16, Issue 4, 2013, Pages 492-497

  Tempestilli, Massimo ^a   Gentilotti, Elisa ^a   Tommasi, Chiara ^a   Nicastri, Emanuele ^a   Martini, Federico ^a   De Nardo, Pasquale ^a   Narciso, Pasquale ^a   Pucillo, Leopoldo P ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Darunavir; Drug interaction; HIV; Lymphocyte; P glycoprotein; Raltegravir

Indexed keywords

DARUNAVIR; MULTIDRUG RESISTANCE PROTEIN; RALTEGRAVIR; RHODAMINE 123; VERAPAMIL;

ADULT; ARTICLE; BLOOD SAMPLING; CELL SURFACE; CONTROLLED STUDY; DONOR; HELPER CELL; HUMAN; IN VITRO STUDY; INCUBATION TIME; LYMPHOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELL MEMBRANE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; FLOW CYTOMETRY; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; LYMPHOCYTES; MIDDLE AGED; P-GLYCOPROTEIN; PYRROLIDINONES; RHODAMINE 123; SUBSTRATE SPECIFICITY; SULFONAMIDES; YOUNG ADULT;

EID: 84878449782     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.05.003     Document Type: Article

References (37)

1. A.R. Zolopa The evolution of HIV treatment guidelines: current state-of-the-art of ART Antiviral Res 85 2010 241 244
2. I. Dierynck, S. De Meyer, E. Lathouwers, C. Vanden Abeele, T. Van De Casteele, and S. Spinosa-Guzman In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients Antivir Ther 15 2010 1161 1169
3. Department of Health and Human Services Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretrovirals agents in HIV-1-infected adults and adolescents http://www.aidsinfo.nih.gov [1-174]
4. M.D. Marsden, and J.A. Zack Eradication of HIV: current challenges and new directions J Antimicrob Chemother 63 2009 7 10
5. K. Goda, Z. Bacsó, and G. Szabó Multidrug resistance through the spectacle of P-glycoprotein Curr Cancer Drug Targets 9 2009 281 297
6. P.G. Hoggard, and A. Owen The mechanisms that control intracellular penetration of the HIV protease inhibitors J Antimicrob Chemother 51 2003 493 496
7. S.U. Sankatsing, J.H. Beijnen, A.H. Schinkel, J.M. Lange, and J.M. Prins P glycoprotein in human immunodeficiency virus type 1 infection and therapy Antimicrob Agents Chemother 48 2004 1073 1081
8. B. Chandler, L. Almond, J. Ford, A. Owen, P. Hoggard, and S. Khoo The effects of protease inhibitors and non-nucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro J Acquir Immune Defic Syndr 33 2003 551 556
9. O. Janneh, E. Jones, B. Chandler, A. Owen, and S.H. Khoo Inhibition of P-glycoprotein and multidrug resistance associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes J Antimicrob Chemother 60 2007 987 993
10. M. Cianfriglia, M.L. Dupuis, A. Molinari, A. Verdoliva, R. Costi, and C.M. Galluzzo HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein Retrovirology 7 2007 4 17
11. L. Bousquet, A. Pruvost, A.C. Guyot, R. Farinotti, and A. Mabondzo Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation Antimicrob Agents Chemother 53 2009 896 902
12. J. Weiss, N. Weis, N. Ketabi-Kiyanvash, C.H. Storch, and W.E. Haefeli Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors Eur J Pharmacol 579 2008 104 109
13. C. Bazzoli, V. Jullien, C. Le Tiec, E. Rey, F. Mentré, and A.M. Taburet Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action Clin Pharmacokinet 49 2010 17 45
14. N. Holmstock, F.J. Gonzalez, M. Baes, P. Annaert, and P. Augustijns PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein Mol Pharm 10 2013 1056 1062
15. C.G. Lee, M.M. Gottesman, C.O. Cardarelli, M. Ramachandra, K.T. Jeang, and S.V. Ambudkar HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter Biochemistry 37 1998 3594 3601
16. J.A. Zastre, G.N. Chan, P.T. Ronaldson, M. Ramaswamy, P.O. Couraud, and I.A. Romero Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line J Neurosci Res 87 2009 1023 1036
17. C.H. Storch, D. Theile, H. Lindenmaier, W.E. Haefeli, and J. Weiss Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein Biochem Pharmacol 73 2007 1573 1581
18. J.H. Lin Drug-drug interaction mediated by inhibition and induction of P-glycoprotein Adv Drug Deliv Rev 55 2003 53 81
19. D. Balayssac, N. Authier, A. Cayre, and F. Coudore Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 156 2005 319 329
20. A. Aszalos Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I Preclinical aspects Drug Discov Today 12 2007 833 837
21. A. Aszalos Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs Curr Drug Metab 9 2008 1010 1018
22. C. Baumert, and A. Hilgeroth Recent advances in the development of P-gp inhibitors Anticancer Agents Med Chem 9 2009 415 436
23. S.K. König, M. Herzog, D. Theile, N. Zembruski, W.E. Haefeli, and J. Weiss Impact of drug transporters on cellular resistance towards saquinavir and darunavir J Antimicrob Chemother 65 2010 2319 2328
24. H. Fujimoto, M. Higuchi, H. Watanabe, Y. Koh, A.K. Ghosh, and H. Mitsuya P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-ransfected renal LLC-PK1 cell lines Biol Pharm Bull 32 2009 1588 1593
25. N.C. Zembruski, G. Büchel, L. Jödicke, M. Herzog, W.E. Haefeli, and J. Weiss Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro J Antimicrob Chemother 66 2011 802 812
26. D.M. Moss, W.S. Kwan, N.J. Liptrott, D.L. Smith, M. Siccardi, and S.H. Khoo Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir Antimicrob Agents Chemother 55 2 2011 Feb 879 887
27. W.T. Beck, T.M. Grogan, C.L. Willman, C. Cordon-Cardo, D.M. Parham, and J.F. Kuttesch Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations Cancer Res 56 1996 3010 3020
28. A. Curran, M. Gutirerrez, E. Deig, G. Mateo, R.M. Lopez, and A. Imaz Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients J Antimicrob Chemother 65 2010 2195 2203
29. J. Moltó, M. Valle, D. Back, G. Mateo, R.M. Lopez, and A. Imaz Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients Antimicrob Agents Chemother 55 2011 72 75
30. E.R. Meaden, P.G. Hoggard, and S.H. Khoo Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo J Immunol Methods 262 2002 159 165
31. M. Egashira, N. Kawamata, K. Sugimoto, T. Kaneko, and K. Oshimi P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833 Blood 93 1999 599 606
32. R. Hayeshi, C. Masimirembwa, S. Mukanganyama, and A.L. Ungell The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux Eur J Pharm Sci 29 2006 70 81
33. M.B. Lucia, S. Rutella, G. Leone, S. Vella, and R. Cauda HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART Acquir Immune Defic Syndr 27 2001 321 330
34. P.G. Hoggard, and D.J. Back Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules Curr Opin Infect Dis 15 2002 3 8
35. E.R. Meaden, P.G. Hoggard, P. Newton, J.F. Tjia, D. Aldam, and D. Cornforth P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals J Antimicrob Chemother 50 2002 583 588
36. D. Mertz, M. Battegay, C. Marzolini, and M. Mair Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus Am J Kidney Dis 54 2009 1 4
37. M. Bickel, E. Anadol, M. Vogel, W.P. Hofmann, N. von Hentig, and J. Kuetscher Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir J Antimicrob Chemother 65 2010 999 1004